Studying lecanemab for early Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have early Alzheimer's disease with mild symptoms (MMSE score between 22 and 30, and a CDR-SB score between 0.5 and 1).
- You must have a positive test for amyloid plaques in the brain (via a PET scan or spinal fluid test).
- You must have completed APOE gene testing (a blood test that checks a risk gene).
- You must be willing to take lecanemab, which is given as an IV infusion.
- You cannot take blood thinners (like warfarin or clopidogrel) or have any condition that increases bleeding risk in the brain.
- You must be able to have an MRI scan and not have certain brain findings, like many small bleeds or a major bleed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
This trial tests a monoclonal antibody therapy—a lab-made protein—to see if it can slow Alzheimer's symptoms. You may qualify if you have early Alzheimer's or mild cognitive impairment with a positive PET scan, and you can't have other major health issues like uncontrolled diabetes or heart problems.
This study registry collects health and brain-testing information for people with mild cognitive impairment or early Alzheimer’s dementia. It may help researchers better understand early Alzheimer disease and plan future treatments.
This trial tests whether a special near-infrared light device, combined with the medication lecanemab, can help people with mild Alzheimer's disease. It aims to see if the light therapy can slow down memory loss and improve daily function.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.